TheraRadar
← Back
Data updated: Jun 28, 2026

PHARMACYCLICS LLC

Specialty
OncologyGastroenterology Execution: Excellent

PHARMACYCLICS LLC is a specialty pharmaceutical company focused on Oncology, Gastroenterology. Key products include IMBRUVICA.

2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PHARMACYCLICS LLC at a Glance

  • Strong track record with 96% execution quality across 34 trials

PHARMACYCLICS LLC's Key Drugs

PHARMACYCLICS LLC's core commercial portfolio centers on IMBRUVICA, spanning Oncology and Gastroenterology — its most strategically important drugs approved in the last 15 years.

IMBRUVICA
Oncology

Mantle Cell Lymphoma

BTK Approved 2013

PHARMACYCLICS LLC's Recent FDA Approvals

New NDA/BLA approvals for PHARMACYCLICS LLC over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHARMACYCLICS LLC's Therapeutic Areas

PHARMACYCLICS LLC's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Gastroenterology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 99%
1 drugs Phase 3: 7 Phase 2: 10 Phase 1: 13
Gastroenterology 1%
0 drugs Phase 1: 1

PHARMACYCLICS LLC's Top Competitors

PHARMACYCLICS LLC's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Johnson & Johnson big-pharma
Oncology, Gastroenterology
Bristol-Myers Squibb big-pharma
Oncology, Gastroenterology
Takeda big-pharma
Gastroenterology, Oncology
PF PRISM CV big-pharma
Oncology, Gastroenterology
ASTELLAS specialty
Oncology, Gastroenterology

PHARMACYCLICS LLC Pipeline Snapshot

PHARMACYCLICS LLC has 31 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 10 Phase 2 and 14 Phase 1.

7
Phase 3
10
Phase 2
14
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • IMBRUVICA leads revenue
  • • Drug-level revenue analysis
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking
View full pipeline →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 9/9 completed
  • • Speed: 47 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges